Free Trial

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Sees Significant Increase in Short Interest

Greenwich LifeSciences logo with Medical background

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 910,700 shares, an increase of 22.5% from the March 31st total of 743,300 shares. Currently, 15.3% of the company's shares are sold short. Based on an average trading volume of 69,700 shares, the days-to-cover ratio is presently 13.1 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright upped their price target on Greenwich LifeSciences from $38.00 to $39.00 and gave the company a "buy" rating in a research note on Monday, April 21st.

Check Out Our Latest Research Report on Greenwich LifeSciences

Greenwich LifeSciences Stock Up 2.1 %

GLSI stock traded up $0.20 during midday trading on Thursday, hitting $9.64. The company's stock had a trading volume of 35,596 shares, compared to its average volume of 45,700. The firm has a 50-day simple moving average of $10.25 and a 200-day simple moving average of $12.01. Greenwich LifeSciences has a 52-week low of $8.06 and a 52-week high of $18.75. The firm has a market capitalization of $127.89 million, a P/E ratio of -12.04 and a beta of 1.74.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last released its earnings results on Tuesday, April 15th. The company reported ($0.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.40). On average, sell-side analysts expect that Greenwich LifeSciences will post -0.8 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Snehal Patel bought 5,500 shares of Greenwich LifeSciences stock in a transaction on Friday, April 4th. The shares were bought at an average cost of $8.73 per share, with a total value of $48,015.00. Following the completion of the purchase, the chief executive officer now directly owns 5,558,002 shares of the company's stock, valued at approximately $48,521,357.46. This trade represents a 0.10 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders have bought 18,100 shares of company stock valued at $164,835. 51.67% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Greenwich LifeSciences

A number of institutional investors and hedge funds have recently modified their holdings of the company. Northern Trust Corp boosted its position in shares of Greenwich LifeSciences by 17.3% during the 4th quarter. Northern Trust Corp now owns 87,423 shares of the company's stock worth $982,000 after acquiring an additional 12,923 shares in the last quarter. Barclays PLC raised its holdings in Greenwich LifeSciences by 323.3% during the third quarter. Barclays PLC now owns 8,560 shares of the company's stock worth $123,000 after purchasing an additional 6,538 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Greenwich LifeSciences by 4.6% during the 3rd quarter. Geode Capital Management LLC now owns 133,550 shares of the company's stock worth $1,919,000 after buying an additional 5,861 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Greenwich LifeSciences by 172.0% in the 4th quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company's stock valued at $79,000 after buying an additional 4,465 shares in the last quarter. Finally, Brown Brothers Harriman & Co. purchased a new position in shares of Greenwich LifeSciences in the 4th quarter valued at $45,000. Institutional investors and hedge funds own 4.16% of the company's stock.

About Greenwich LifeSciences

(Get Free Report)

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

Featured Articles

Should You Invest $1,000 in Greenwich LifeSciences Right Now?

Before you consider Greenwich LifeSciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Greenwich LifeSciences wasn't on the list.

While Greenwich LifeSciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines